GlobeNewswire Inc | Dec 10, 2021 07:30AM EST

December 10, 2021

PALO ALTO, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on December 6, 2021, the compensation committee of BridgeBios board of directors granted nine new employees restricted stock units for an aggregate of 12,073 shares of the Companys common stock. All of the above-described awards were made under BridgeBios 2019 Inducement Equity Plan (the Plan).

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBios board of directors in November 2019.

About BridgeBioBridgeBio Pharma (BridgeBio) is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBios pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the companys first two approved therapies. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visitbridgebio.comand follow us onLinkedInandTwitter.

Media ContactGrace RauhGrace.rauh@bridgebio.com(917) 232-5478

Source: BridgeBio Pharma, Inc.